Dr. Rampal on the Investigation of Navtemadlin in Relapsed/Refractory AML and MPNs

Raajit K. Rampal, MD, PhD, hematologic oncologist, Memorial Sloan Kettering Cancer Center, discusses the investigation of navtemadlin (KRT-232) in relapsed/refractory acute myeloid leukemia (AML) and patients with blast phase myeloproliferative neoplasm (MPN) in a phase 1b/2 trial (NCT04113616).

This actively accruing trial is examining the safety and efficacy of navtemadlin, a novel oral small molecule MDM2 inhibitor.

Specifically, the trial is evaluating patients with blast phase MPN in patients, defined as those who have more than 20% blasts in the bone marrow or peripheral blood, Rampal says. Moreover, this study will examine patients who have had at least 1 line of therapy without response or who have relapsed disease following prior response, Rampal explains. These factors account for a majority of patients, as conventional therapies do not appear to be very effective, Rampal adds.

The trial initially was meant to examine an MDM2 inhibitor combined with hypomethylating agents or chemotherapy, Rampal continues. However, the trial is now focusing on navtemadlin as a single agent and is exploring dosing strategies, Rampal concludes.